Table 1. Characteristics of patients sensitive to gefitinib (G) and erlotinib (E)
Patient Sex Smoking Histology Mutation Duration OS
G1 M Former BWFI del E746-A750* 5+ 5+
G2 F Never AWBF del E746-A750 28 30+
G3 F Never AWBF del L747-S752* 18 23+
G4 F Never AWBF del E746-T751 insl 9 14
G5 M Never AWBF del E746-A750 8 15
G6 M Never AWBF del E746-A750 5+ 5+
G7 F Former ADENO L858R 5 8
G8 F Never AWBF None 7+ 7+
G9 M Former BAC None 10+ 10+
G10 F Never SQUAM None 9 16
E1 M Never AWBF del L747-S752insQ 8+ 8+
E2 M Never BAC del E746-A750 8.5 21+
E3 F Never AWBF R776C and L858R 13 22+
E4 M Former AWBF L858R 3 3.5
E5 F Never AWBF L858R 6 17+
E6 F Former AWBF None 11 11+
E7 F Former AWBF None 11 14+
  • M, male; F, female. Smoking indicates smoking history; never, smoked <100 cigarettes in a lifetime; former, smoked 100 or more cigarettes and quit > 1 year prior to diagnosis of lung cancer. BWFI, BAC with focal invasion; AWFB, adenocarcinoma with BAC features; ADENO, adenocarcinoma; SQUAM, squamous. Mutation indicates amino acids affected in EGFR; for all tumor specimens, exons 18-24 of EGFR, which encode the TK domain, were examined; asterisks denote homozygous deletions; none, no mutation observed. Duration indicates months of drug-induced response. OS indicates months of overall survival after starting therapy with gefitinib or erlotinib. +, still on drug and/or alive at the time of writing of this manuscript. No mutations were observed in exons 18-24 in 8 and 10 patients refractory to gefitinib and erlotinib, respectively.